Brokerages expect that Bristol-Myers Squibb Co (NYSE:BMY) will announce earnings of $0.84 per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Bristol-Myers Squibb’s earnings. The highest EPS estimate is $0.85 and the lowest is $0.81. Bristol-Myers Squibb posted earnings of $0.68 per share during the same quarter last year, which would indicate a positive year over year growth rate of 23.5%. The company is scheduled to issue its next quarterly earnings report before the market opens on Thursday, January 24th.
On average, analysts expect that Bristol-Myers Squibb will report full year earnings of $3.87 per share for the current year, with EPS estimates ranging from $3.84 to $3.89. For the next year, analysts expect that the business will post earnings of $4.08 per share, with EPS estimates ranging from $3.89 to $4.26. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion.
Several research analysts have recently issued reports on the company. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday. JPMorgan Chase & Co. raised their price objective on Bristol-Myers Squibb from $70.00 to $74.00 and gave the stock an “overweight” rating in a research note on Monday, October 8th. BMO Capital Markets raised their price objective on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a research note on Friday, November 16th. Societe Generale set a $47.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Wednesday, November 14th. Finally, William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.95.
Shares of NYSE:BMY traded down $0.17 during trading on Friday, hitting $53.08. The stock had a trading volume of 9,402,802 shares, compared to its average volume of 7,962,205. Bristol-Myers Squibb has a 12-month low of $46.94 and a 12-month high of $70.05. The stock has a market cap of $86.91 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 1.48 and a beta of 1.11. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41.
The business also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Investors of record on Friday, January 4th will be issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 3.09%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
Institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP grew its holdings in Bristol-Myers Squibb by 19.3% in the third quarter. Marshall Wace LLP now owns 867,621 shares of the biopharmaceutical company’s stock valued at $53,862,000 after purchasing an additional 140,539 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 10.1% in the third quarter. Great Lakes Advisors LLC now owns 99,612 shares of the biopharmaceutical company’s stock worth $6,184,000 after acquiring an additional 9,162 shares during the last quarter. Clearbridge Investments LLC boosted its stake in shares of Bristol-Myers Squibb by 12.7% in the third quarter. Clearbridge Investments LLC now owns 3,059,262 shares of the biopharmaceutical company’s stock worth $189,919,000 after acquiring an additional 344,278 shares during the last quarter. Carnegie Capital Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 18.2% in the third quarter. Carnegie Capital Asset Management LLC now owns 145,575 shares of the biopharmaceutical company’s stock worth $7,880,000 after acquiring an additional 22,461 shares during the last quarter. Finally, Belpointe Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 7.4% in the third quarter. Belpointe Asset Management LLC now owns 171,598 shares of the biopharmaceutical company’s stock worth $10,653,000 after acquiring an additional 11,766 shares during the last quarter. 72.74% of the stock is currently owned by hedge funds and other institutional investors.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Further Reading: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.